Edwards Lifesciences Longtime Chair To Retire
By Ben Glickman
Edwards Lifesciences said Tuesday that chair Michael Mussallem planned to retire about a year after stepping down as chief executive.
The Irvine, Calif.-based company said in a regulatory filing that Mussallem, who served as CEO of Edwards from 2000 to 2023, is expected to be succeeded as chair by Nicholas Valeriani, an independent director.
Mussallem retired as CEO at the 2023 annual meeting, transitioning into the non-executive chair role. He was succeeded in the CEO role by Bernard Zovighian.
The company's annual meeting is scheduled for May 7.
Edwards said in the filing that board member Martha Marsh had reached the retirement age outlined in the company's governance guidelines.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
March 26, 2024 16:42 ET (20:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Boeing Stock a Buy, a Sell, or Fairly Valued?